glp-1 and cardiovascular benefits Drugs & What They Do GLP-1 Receptor Agonists in the
Description
Most practitioners report that their microdosing patients experience zero gastrointestinal side effects
It cannot accurately capture reductions in hepatic glycogen or liver fat, both of which are known to decrease dramatically with GLP-1 treatment
Liraglutide is also subject to post-marketing surveillance by the FDA as doctors and scientists continue to monitor its safety and efficacy
It's the same drug, but Wegovy can be prescribed in larger doses
No funding was received to assist with the preparation of this manuscript
